Trials on veterans suggest ibogaine could provide a new treatment for PTSD

Original Article ↗ Hacker News Discussion ↗

Choice of ibogaine vs other psychedelics

  • Several commenters question why ibogaine is chosen over alternatives like psilocybin, LSD, DMT, or Salvia divinorum, which are seen as safer or less cardiotoxic.
  • Others argue ibogaine’s specific pharmacology (kappa-opioid activity, effects on serotonin/NMDA, possible neurotrophic effects) may uniquely help with PTSD and traumatic brain injury (TBI).
  • There is debate over whether similar psychological effects could be achieved with cheaper or legal substances like DXM.

Safety, cardiotoxicity, and evidence quality

  • Some describe ibogaine as “horribly unsafe” for the heart, requiring intensive monitoring; others say risks are manageable with proper screening and magnesium supplementation.
  • Multiple deaths linked to ibogaine are noted, including ones reported as occurring in clinical contexts; another commenter counters that at least one such case involved serious provider negligence.
  • A cited open-label brain-imaging study suggesting structural changes after ibogaine is criticized for lacking a control group.

Veteran focus and political framing

  • Many question why trials emphasize veterans over larger PTSD populations (e.g., assault survivors). Explanations offered: easier recruitment via the VA system, better medical records, strong political support for veteran-focused research, and defense-related funding.
  • Some see this as neglect of non-veteran PTSD sufferers; others say starting with a homogeneous group is scientifically cleaner.

Addiction, PTSD, and TBI mechanisms

  • Longstanding use of ibogaine for opioid and alcohol addiction is discussed, with mixed anecdotal reports: from “life-changing” to no lasting benefit.
  • One view reduces ibogaine to “just another opioid,” while others emphasize that treatment is typically a one-off session, not maintenance.
  • There is argument over whether PTSD is fundamentally brain damage (e.g., concussion/shell shock) or a psychological trauma response; several commenters insist the standard definition does not require head injury.

Comparison to other treatments

  • Some ask why established interventions like ECT or TMS get less attention despite strong evidence for severe depression, while others highlight ECT’s risks, cognitive side effects, and traumatic experiences.
  • Comparisons are drawn to SSRIs and other mental health tradeoffs: partial relief with side effects may still be worthwhile.

Therapeutic ecosystem and commercialization

  • Concerns are raised about “therapeutic cults” and wellness pseudoscience around illegal psychedelics, underscoring the need for careful, regulated clinical trials.
  • Others complain about regulatory “red tape,” while some support strict oversight given ibogaine’s risk profile.